Superseded public profile

In clinical trials↗Metabolic↗

Superseded · version 2: Pemvidutide↗

Related names recorded in this version: ALT-801↗

A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Update · July 27, 2026

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change. 1

What this version reported

ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.↗

Organizations named in cited records:
  • Altimmune, Inc.↗

Trial records: NCT05989711

Sources for this version

  1. 1
    IMPACT: Pemvidutide in Participants With NASH · record history version 10 · last update posted 2026-05-18 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026